Vanda Pharmaceuticals Inc. SEC filings VNDA
Vanda Pharmaceuticals Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 10, 2009. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 4, 2026 |
| DEFA14A | Additional proxy material | May 27, 2025 | — |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | May 13, 2024 | — |
| DEFA14A | Additional proxy material | May 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | May 17, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| DEF 14A | Proxy statement | Apr 24, 2023 | — |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 16, 2022 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | May 26, 2020 | — |
| DEFA14A | Additional proxy material | Apr 22, 2020 | — |
| DEF 14A | Proxy statement | Apr 22, 2020 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Apr 25, 2019 | — |
| DEF 14A | Proxy statement | Apr 25, 2019 | Jun 13, 2019 |
| DEFA14A | Additional proxy material | Jun 1, 2018 | — |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 13, 2018 |
| DEFA14A | Additional proxy material | Apr 27, 2017 | — |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 15, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Apr 29, 2015 | — |
| DEF 14A | Proxy statement | Apr 29, 2015 | Jun 18, 2015 |
| DEFA14A | Additional proxy material | Apr 7, 2014 | — |
| DEF 14A | Proxy statement | Apr 7, 2014 | May 22, 2014 |
| DEFA14A | Additional proxy material | Apr 26, 2013 | — |
| DEF 14A | Proxy statement | Apr 26, 2013 | Jun 20, 2013 |
| DEFA14A | Additional proxy material | Apr 30, 2012 | — |
| DEF 14A | Proxy statement | Apr 30, 2012 | Jun 14, 2012 |
| DEFA14A | Additional proxy material | Apr 29, 2011 | — |
| DEF 14A | Proxy statement | Apr 29, 2011 | May 16, 2011 |
| DEF 14A | Proxy statement | Apr 28, 2010 | Jun 3, 2010 |
| DEF 14A | Proxy statement | Jul 13, 2009 | Aug 27, 2009 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.